公司資料
Aclaris Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ACRS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
6.31 USD (-1.56%)
收盤價
最後更新: 2026年8月24日
647M USD
市值
股價為何變動
As of Aug 24, 2026, ACRS closed down 1.56% at $6.31. No new same-company headline was identified in the current news window.
公司概覽
Immuno-Inflammatory Drug Development
Aclaris Therapeutics develops biologic and oral therapies for immuno-inflammatory diseases. Its portfolio targets upstream cytokines and intracellular signaling pathways.
ATI-052
ATI-052 is a long-acting bispecific antibody against TSLP and IL-4 receptor alpha in proof-of-concept studies for asthma and atopic dermatitis.
Bosakitug
Bosakitug is an anti-TSLP monoclonal antibody in Phase 2 development for atopic dermatitis.
ATI-2138
ATI-2138 inhibits ITK and JAK3 and is being advanced through a Phase 2b basket strategy covering multiple forms of lichen planus.
ATI-9494
ATI-9494 is a next-generation oral ITK inhibitor approaching IND submission for broader immuno-inflammatory development.
未來催化劑
- Topline Phase 1b data for ATI-052 in asthma and atopic dermatitis in the second half of 2026.
- Initiation of the first part of a Phase 2b lichen-planus study of ATI-2138 in the second half of 2026.
- IND submission for ATI-9494 in the second half of 2026.
- Initiation of a Phase 2b asthma program for ATI-052 in the fourth quarter of 2026.
- Topline Phase 2 data for bosakitug in the fourth quarter of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。